According to two prostate cancer studies from Taylor and TCGA, lower expression levels of CES1 were associated with prostate cancer, a higher Gleason score, a more advanced stage, and worse survival in patients (Figure 2B,C). This evidence concerns the gene CES1 and prostate carcinoma.